Rimonabant--A Selective CB1 Antagonist -- Boyd and Fremming 39 (4): 684 -- The Annals of Pharmacotherapy Website
OBJECTIVE: To review the pharmacology, pharmacokinetics, clinicalefficacy, and safety of rimonabant, a new selective cannabinoid receptorantagonist. DATA SOURCES: Primary literature and review articl
added by janecw on 2007-04-12 18:58:05